HOME > ARCHIVE
ARCHIVE
- R&D NEWS IN BRIEF
June 6, 2005
- Nikken Chemicals: Profits Up Sharply Despite Lower Sales
June 6, 2005
- NEW PRODUCTS
June 6, 2005
- Teikoku Hormone: Profits Up Despite Slight Dip in Sales
June 6, 2005
- REGULATORY NEWS IN BRIEF
June 6, 2005
- Yakult Honsha: Pharma Div. Sees 2.1% Decline in Sales
June 6, 2005
- Kobayashi: Sales Up 1.9% at \215,708 Mil.
June 6, 2005
- Seikagaku Corp.: 8.8% Increase in Sales to \22,564 Mil.
June 6, 2005
- Mediceo HD: Sales Rise 29.7% to \1,665,815 Mil.
June 6, 2005
- Taiyo Pharm. Expects Over \32 Billion in Sales in FY2005
June 6, 2005
- Shionogi: Profits Up Despite Dip in Sales
May 30, 2005
- OTC NEWS IN BRIEF
May 30, 2005
- Dainippon: Stronger Focus Boosts Operating, Ordinary Profits
May 30, 2005
- SURVEY 3 articles
May 30, 2005
- Ono: Major Products Bolster Growth in Sales, Profits
May 30, 2005
- Sales Up 0.3%, Net Profits Down 3.1% for Top Domestic Pharma Companies
May 30, 2005
- Kissei: Sales Rise 4.6% to \60,933 Bil.
May 30, 2005
- Mochida: Consolidation, R&D Investment Cut into Profits
May 30, 2005
- Meiji Seika: Pharmaceutical Sales Rise 0.9% to \109,530 Mil.
May 30, 2005
- Nippon Shinyaku: Development of Urespan, Tramadol Takes Time
May 30, 2005
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
